| Name | TCJL37 | 
|---|
| Description | TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a Ki of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD)[1]. | 
|---|---|
| Related Catalog | |
| Target | Tyk2:1.6 nM (Ki) | 
| In Vitro | In cell-based assays, TCJL37 (Compound 37) shows IL-12 pSTAT4 EC50 of 224 nM. TCJL37 shows EC50s of 168 nM and 737 nM In human peripheral blood mononuclear cells (PBMC) and human whole blood assay, respectively[1]. | 
| In Vivo | TCJL37 exhibits excellent oral exposure in CD-1 mice following oral administration (100 mg/kg). TCJL37 exhibits low clearance (1.0 mL/min/kg) in rat[1]. | 
| References | 
| Molecular Formula | C17H11ClF2N4O2 | 
|---|---|
| Molecular Weight | 376.74 |